Breast Cancer Cell Line Development Service
Breast cancer cell line development creates and optimizes cell lines that accurately reflect breast tumors. These cell lines are crucial for studying cancer biology, testing therapies, and understanding drug resistance. They provide a consistent model for exploring treatment effects and molecular mechanisms. Alfa Cytology offers a comprehensive suite of breast cancer cell line development services tailored for research and clinical applications.
Overview of Breast Cancer Cell
Breast cancer (BC) refers to a malignant tumor in which the breast's glandular or ductal epithelial cells become cancerous, ranking first in the incidence of female malignant tumors. Bioengineering techniques are increasingly applied to designing and constructing patient-specific models to understand the unique biological properties of BC and facilitate the research of new therapeutic targets. BC cell models are important and powerful tools for BC research. Much of what researchers know about BC is based on studies of BC cell lines in vivo and in vitro. Although there are more commonly used BC organoid models or animal models, BC cell models are still indispensable in BC research.
Breast cancer cell culture classification by morphological structure. (Witt BL, 2023)
Our Services
Alfa Cytology can provide you with in vitro cell models of BC, including 2D cell lines and 3D spheroids, and we are committed to helping researchers study BC in an efficient, cost-effective, and effective manner. 2D cell culture is the easiest, fastest, and most economical format to study metastasis and invasion. Furthermore, by co-culturing cancer cells with stromal cells, 2D cell culture can be used to mimic signals from tumor microenvironment (TME) tumors and compound screening for antitumor drugs.
| BC 2D cell lines from Alfa Cytology | |
|---|---|
| luminal A | MCF-7 |
| luminal B | T47D, BT474, ZR75.1 |
| HER2+ | SKBR3, UACC-893 |
| TNBC | MDA-MB-231, MDA-MB-468, BT20, HCC38, HCC1937, HCC1806, SUM149, SUM159, SUM1315 |
The spheroid is the first 3D cancer cell model, and BC 3D spheroid model can more accurately reflect BC tumor biology and tumor microenvironment. Our modeling techniques include static approaches such as scaffold-free methods of hanging drop, liquid overlay on ultra-low attachment plates, and micropatterned plates, and dynamic approaches such as spinner flask, rotating vessels, microfluidic systems or techniques using scaffolds. We will customize the best model for you based on your needs.
Advantages of BC Cell Models
- Homologous, easy to replicate, easy to cultivate
- Infinitely proliferative
- Applicable to a large number of experiments such as high-throughput drug screening
Application Fields
Case Study
MDA-MB-231Cell Line
- Model Introduction
The MDA-MB-231 cell line, derived from the pleural effusion of a patient with metastatic breast adenocarcinoma, serves as a fundamental model for investigating the pathogenesis of triple-negative breast cancer (TNBC), particularly focusing on the mechanisms underlying tumor invasion, metastasis, and drug resistance.
- Model Information
- Origin: Human metastatic site (pleural effusion).
- Classification: A triple-negative breast cancer (TNBC) cell line (ER-, PR-, HER2-).
- Genetic Background: Harbors a mutant p53 gene.
- Morphology: Epithelial-like, predominantly exhibiting a spindle-shaped morphology.
- Growth Pattern: Adherent.
- Key Markers: Characterized by high expression of EGFR, and expression of oncogenes such as WNT7B.
- Cancer Type: Triple-Negative Breast Cancer (TNBC)
- Model Validation (In Vivo)
An orthotopic breast cancer model was established by inoculating MDA-MB-231 cells (1×10⁷ cells/mouse) into the mammary fat pads of 7-week-old immunodeficient C-NKG and NOD-Scid mice. Tumor growth was monitored longitudinally, and data are expressed as mean ± SEM. The model exhibited consistent and efficient tumor engraftment in both mouse strains. Tumor volume progression followed a predictable kinetic profile, reaching an estimated 100-200 mm³ by day 25 and achieving the study endpoint volume of 1000 mm³ by day 55 post-inoculation. Based on this growth kinetics, the therapeutic intervention window was projected to commence around day 30.
Fig. 2 Tumor and body weight growth curve of breast cancer cell MDA-MB-231 transplanted into breast pad (n=6).(Source: Alfa Cytology)
Alfa Cytology is an advanced CRO company with years of experience in building BC cell models. Based on our advanced platform and experienced scientists, we can build customized, cost-effective, high-quality BC cell models for BC drug and therapy development research. If you are interested in learning more about our BC cell model services, please contact us. We will provide you with a professional and competitively priced strategy as soon as possible to meet your needs.
Reference
- Witt BL, Tollefsbol TO. Molecular, Cellular, and Technical Aspects of Breast Cancer Cell Lines as a Foundational Tool in Cancer Research. Life, 2023, 13(12): 2311.